spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  heparin-induced thrombocytopenia 

 HSMN NewsFeed - 23 Jun 2021
Veralox Therapeutics Appoints Michael Hanna As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jun 2021
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Nov 2015
Akers Biosciences Appoints Medical Technology Specialist as CEO
Diagnostics Personnel
 HSMN NewsFeed - 9 Jul 2015
The Medicines Company Authorizes Generic Launch of ANGIOMAX(R) (bivalirudin)
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 18 Dec 2014
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 25 Jun 2014
Akers Biosciences Signs Agreement With Medline -- a Major US Distributor
Diagnostics Distribution
 HSMN NewsFeed - 30 Oct 2013
The Medicines Company's EUROMAX Trial of Angiox(R) (Bivalirudin) in Heart Attack Meets All Prespecified Endpoints
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Oct 2013
First Patient Enrolled in Phase III Trial Evaluating The Medicines Company's Angiomax(R) (Bivalirudin) in Patients Undergoing Peripheral Endovascular Procedures
Biopharmaceuticals Interventional
 HSMN NewsFeed - 28 Aug 2012
Latest European Heart Attack Treatment Guidelines Recommend Angiomax(R)/Angiox(R) (Bivalirudin) Over Heparin
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Apr 2010
Comparative Trial of Canyon's Iprivask(R) (Desirudin) with Standard of Care Shows Favorable Outcomes for Thrombosis Prophylaxis in Surgery Patients with HIT
Biopharmaceuticals
 HSMN NewsFeed - 19 Jun 2009
FDA Grants The Medicines Company Pediatric Exclusivity for Angiomax(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Sep 2008
New Analysis From HORIZONS-AMI Shows Major Bleeding Has a Significant Impact and Contributes to 30-Day Mortality Following Angioplasty in Severe Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Aug 2008
ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 May 2008
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 22 May 2008
Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted in Improved Survival Rates in the Most Severe Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Mar 2008
Angiomax Demonstrated Improved Outcomes in Acute Heart Attack Patients Undergoing Primary Angioplasty Independent of Individual Risk Factors
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 2 Jan 2008
Barr Confirms Patent Challenge of Argatroban(R)
Biopharmaceuticals Litigation
 HSMN NewsFeed - 28 Dec 2007
Encysive Pharmaceuticals Announces Patent Infringement Lawsuit Against Barr Laboratories
Biopharmaceuticals Litigation
 HSMN NewsFeed - 4 Dec 2007
Journal of the American Medical Association (JAMA) Publishes One-Year ACUITY Trial Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Oct 2007
Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Sep 2007
Angiox(R) (Bivalirudin) Alone Reduced Early Bleeding and Resulted in Similar One-Year Mortality Compared to Heparins Plus GP IIb/IIIa Combination Therapy in ACS Patients Undergoing Angioplasty
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Apr 2007
The Lancet Publishes PREVAIL Study Results Showing Lovenox(R) Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
New Study Shows Lovenox(R) (Enoxaparin Sodium Injection) Is More Effective Than Unfractionated Heparin (UFH) for Lowering the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 2 Oct 2006
FDA Grants Priority Review for ARIXTRA(R) (fondaparinux sodium) in the Treatment of Acute Coronary Syndromes
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 7 Sep 2006
The New England Journal of Medicine Publishes the STEEPLE Study Which Demonstrated Superior Safety Profile of LOVENOX(R)(Enoxaparin Sodium Injection) Vs. Unfractionated Heparin in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention (PCI)
Biopharmaceuticals Interventional Cardiology
Return to NewsFeed  

 Additional items found! 58

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 58 additional stories matching:
heparin-induced thrombocytopenia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.